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Summary 
Increasing evidence suggests that therapy-resistance in solid tumors is 
partly due to the protective effect of the microenvironment on neoplastic 
cells. Cross-talk between tumor cells and their microenvironment is partly 
coordinated by G-protein coupled receptors (GPCRs) which are implicated in 
many facets of solid tumors, including cancer cell proliferation, production 
of angiogenic factors and metastasis [1-3]. Therefore, in this thesis we aimed 
to study two membrane bound receptors, namely formyl-peptide receptor-1 
(FPR1) and chemokine receptor-4 (CXCR4). Both receptors are highly involved 
in tumor cell migration, triggered by cognate ligands present in the tumor 
microenvironment. 
Chapter 1 provides a general introduction to glioblastoma (GBM) and GPCRs 
including the aim of the thesis and the chapter outline. Despite the available 
treatment options of surgical resection and radio-chemotherapy, GBMs 
invariably show recurrence. A number of treatment options are available after 
recurrence, amongst which the anti-angiogenic treatment with bevacizumab 
has been extensively explored. However therapy resistance develops soon, 
which is partly due to neovascularization. To better understand the course of 
neovascularization following bevacizumab therapy, we performed in Chapter 
2 a literature review about the recruitment of bone marrow derived cells 
(BMDC) involved in the process of therapeutic resistance. GBMs are highly 
vascularized tumors characterized by rapid and invasive tumor growth, 
typically followed by oxygen depletion and neovascularization, all resulting 
in a network of disorganized, tortuous and permeable vessels. Acute hypoxia 
following prolonged vascular endothelial growth factor (VEGF-A) depletion 
induces the recruitment of BMDC, which may contribute to treatment 
refractoriness. These cells may act as vascular progenitors by integrating 
into the newly formed vessels or as vascular modulators by releasing 
pro-angiogenic factors. BMDC recruitment plays a prominent role in the 
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refractoriness to anti-VEGF treatment. Therefore bevacizumab therapy might 
benefit when combined with other treatment modalities targeting the BMDC 
recruitment as compared to single agent use. As such, this chapter also 
elaborates on possible anti-VEGF combination strategies, including targeted 
therapy against Tie-2 and/or its two ligands angiopoietin 1 and 2 (Ang1/2), 
CXCR4, placental derived growth factor (PlGF) and platelet derived growth 
factor-β (PDGF-β), to improve GBM treatment outcome. 
Tie-2 has been originally described together with Ang1 and Ang2 for its 
involvement in vessel stabilization and destabilization. However recent 
studies reported certain types of monocytes marked by the expression of 
Tie-2 and therefore dubbed Tie-2 expressing monocytes (TEM). In Chapter 
3 we semi-quantitatively evaluated the expression of Ang1, Ang2 and Tie-
2 in a series of 50 immunostained GBM patient samples. Tie-2 expression 
was correlated with patient survival and angiogenic data (consisting of tumor 
microvessel density, tumor cell proliferation and tumor cell apoptosis data). 
By using immunofluorescent double staining of Tie-2 with glial acidic fibrillary 
protein (GFAP) or with CD163, we determined whether Tie-2 was expressed 
by glial tumor cells or microglia/tumor associated macrophages. Hundred 
percent of GBMs were positive for Ang1 and 98% were positive for Ang2. 
Semi-quantitative Ang1 and 2 scores did not correlate with patient survival 
or angiogenic data. We observed a high Tie-2 expression on TEMs and to a 
lesser extent on endothelial cells (vascular compartment) and tumor cells. In 
addition Tie-2 expression negatively correlated with overall patient survival 
(P = 0.05) but not with angiogenic data. Overall this chapter describes the 
presence of TEMs in a larger series of GBM and the negative correlation 
of Tie-2 expression with patient survival, suggesting the importance of the 
angiopoietin/Tie-2 system in GBM. 
Conspicuous evidence indicates that in tumors, CXCR4 highly contributes to 
the microenvironment mediated cancer therapy resistance [4]. Therefore 
the inhibition of CXCR4 with AMD3100 is deemed an interesting approach 
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for cancer therapy. However results from several different (pre-)clinical 
studies on AMD3100 treatment in different contexts show a dichotomous 
function of this inhibitor. On the one hand it was previously reported for its 
anti-metastatic effects in ovarian [5] and breast cancer [6], oral squamous 
carcinoma [7] and for sensitizing cells to treatment when combined with 
chemotherapy in gliomas and prostate cancer [8,9]. On the other hand it 
is used to stimulate hematopoietic CXCR4-expressing stem cell mobilization 
for autologous stem cell transplantation in non-Hodgkin’s lymphoma and 
multiple myeloma patients [10,11]. In Chapter 4 we studied the effects of 
CXCR4 inhibition combined with irradiation in human prostate cancer cells 
and investigated whether AMD3100 treatment also affects mobilization of 
tumor cells. In an in vitro co-culture with stromal cells we observed that 
the CXCR4 inhibitor AMD3100 sensitized prostate cancer cell lines PC3-Luc 
and LNCaP to irradiation. Combined treatment of mice xenografted with 
luciferase-expressing PC3-luc cells with radiotherapy and AMD3100, resulted 
in reduced tumor volumes at the fourth week of treatment as compared 
to either treatment alone. Immunohistochemically stained prostate cancer 
xenografts from irradiated mice showed higher CXCR4 and CXCL12 expression 
as compared to controls. However, bioluminescent imaging of blood 
samples from these animals revealed that AMD3100 also mobilized tumor 
cells as measured at days 14 (83-fold increase, P < 0001) and 21 (33-fold 
increase, P < 0001) in comparison with baseline measurements. Although 
not significantly, AMD3100 also increased the number of metastases as 
assessed at termination. In conclusion this chapter shows that AMD3100 
transiently enhances prostate cancer radiosensitivity, but induces cancer cell 
mobilization and slightly increases metastasis.
FPR1 is member of the GPCR network involved in cancer biology which is 
highly present in grade IV astrocytoma (GBM). It is expressed by the human 
GBM cell line U87 in which ligand induced activation of FPR1 promotes tumor 
cell motility, growth and angiogenesis [12,13]. In Chapter 5, we aimed to 
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further define the role of FPR1 in GBM.
We performed an immunohistochemical evaluation of FPR1 expression  in 
tumor samples of 32 patients diagnosed with astrocytomas grades I-IV (8 
patient samples for each grade). FPR1 was detected in 29 out of 32 (90%) 
tumors. In addition we performed in vitro experiments with U87 GBM cell line 
and a FPR1 transfected human promonocytic cell line U937-FPR. In calcium 
mobilization assays, activation of U87 and U937-FPR cells with a bacterial 
derived agonist, fMLF, could be inhibited with Chemotaxis Inhibitory Protein of 
S. aureus (CHIPS) up to 80% (U87) and 10-fold (U937-FPR). Activation of U937-
FPR cells exhibited upregulation of calcium mobilization when stimulated 
with mitochondrial derived agonists fMMYALF (3-fold) and fMLKLIV (4-fold) 
which could be completely inhibited with 1 µg/mL CHIPS. Migration induced 
by fMLF could be inhibited with CHIPS up to 100% (U87) and 86% (U937-FPR). 
Migration induced by fMMYALF and fMLFKLIV on U937-FPR reached up to 
75% and 77% inhibition respectively by CHIPS. In addition U87 stimulated 
with fMLF induced phosporylation of AKT and ERK1/2 as measured with 
Western blot and the production of VEGF as measured by ELISA, could  be 
inhibited with CHIPS. Finally in vivo CHIPS treatment versus vehicle treatment 
improved survival of mice bearing U87 subcutaneous xenografts (P = 0.0019). 
The results of this study indicate that formylated peptides, including those 
of mitochondrial origin, present in the microenvironment of necrotic cells, 
activate FPR1 and that all responses could be inhibited with CHIPS. Therefore 
FPR1 might be a target of interest for the development of novel therapies to 
improve treatment results for GBM patients. 
The overall high expression pattern of FPR1 in GBM samples prompted us 
to further investigate the expression profile in a large panel of GBM patient 
specimens. Therefore in Chapter 6 we evaluated the FPR1 expression in 
an extended panel of human GBMs. We investigated the possibility to 
elicit agonist induced FPR1 activation in GBM cell lines and to inhibit these 
responses with CHIPS. All 178 GBM patient specimens expressed FPR1. 
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Activation of FPR1 in U87 cells by fMLKLIV and fMMYALF was measured by 
increased calcium mobilization, AKT and ERK1/2 phosphorylation, and ligand-
directed migration. All responses could be inhibited by CHIPS. FPR1 mRNA 
and functional activity could not be detected in any of the 8 primary human 
GBM cell lines (dubbed GG 1/6/7/9/12/13/14/16) tested. However FPR1 was 
expressed in all tumor samples from which the GG cell lines were originally 
isolated. In addition immunofluorescent staining of GBM slides revealed FPR1 
expression on microglia/tumor associated macrophages (CD68+/CD163+ 
cells) and glial tumor cells (GFAP+ cells). Finally brain sections of orthotopic 
xenografts of GG cell lines revealed specific FPR1 staining. In conclusion FPR1 
is widely expressed in GBM  and can be activated by human mitochondrial-
derived agonists in U87 cells. Although FPR1 expression could not be detected 
in GG cell lines in vitro, when engrafted in mouse brains these cells show 
FPR1 expression. This implicates that the microenvironment potentially plays 
a role in modulating FPR1 expression.
FPR1 was highly expressed in GBM samples and CHIPS was a potent inhibitor 
of formylated peptide induced responses, therefore CHIPS remains a 
potential interesting drug for the treatment of GBM patients. CHIPS has been 
previously tested in a small phase I clinical trial as an anti-inflammatory drug. 
However due to pre-existing circulating anti-CHIPS antibodies, side effects 
were observed upon intravenous administration. Given the immunogenicity 
effects of CHIPS, the quest for less immunogenic CHIPS variants containing 
the same FPR1 binding affinity was investigated in Chapter 7. We used an 
Escherichia coli expression system to develop a number of CHIPS-mutants. 
Calcium mobilization assays with neutrophils revealed that the substitution 
of 3 amino acids (aa) at position 69-71 and deletion of aa 7-56 (α-helix) or 
aa 7-30 (first spacer), affected the binding capacity of CHIPS to FPR1. Pre-
treatment of neutrophils with CHIPS-based and FLIPr-based N-terminal 
peptide fragments containing the first 6 to 20 aa inhibited calcium 
mobilization. However peptide fragments were on average 10,000 times less 
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potent than the CHIPS protein. Finally with a less immunogenic CHIPS variant 
called CHIPS-JC, FPR1 inhibition could be achieved with calcium mobilization 
assays but not migration assays. 
Discussion and Future Perspectives
The exploration of new therapeutic options, which aimed at overcoming 
treatment resistance of solid tumors, has primarily focused on targeting 
tumor cells and proven very difficult to achieve. The notion that therapy 
resistance is largely conferred by the microenvironment in solid tumors has 
turned it into an important potential target for new anti-cancer treatment 
approaches. 
 
Cut the cross-talk: isolating tumor cells from their microenvironment 
Tumor cells communicate with their environment by modulating the 
surrounding cells to induce enhanced growth and survival. As presented 
in Chapter 2, many different factors produced by cancer cells induce the 
recruitment of bone marrow cells thereby contributing to therapy resistance. 
As presented in Chapter 3, the extra-endothelial expression of Tie-2 in GBM 
and its negative correlation with patient survival led us to the conclusion 
that Tie-2 expression is a negative prognostic factor in these tumors. Tie-2 
in GBM has been previously reported to mediate therapy resistance. Tumor 
stem cells isolated from surgical samples of human glioblastoma and treated 
with a panel of cytotoxic and chemotherapeutic drugs were highly resistant 
when they expressed Tie-2 [14]. Furthermore in an intracranial glioma 
mouse model in which Tie-2 positive glioma cells, when co-transplanted 
with endothelial cells, regulated tumor cell invasiveness [15]. In a mouse 
mammary tumor virus (MMTV) pyMT mammary carcinoma mouse model 
a conditional Tie-2 knock down in TEMs was investigated. The knock down 
of Tie-2 prevented the interaction of TEMs with blood vessels even inducing 
regression of the vasculature [16]. All together these findings strongly 
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indicate that Tie-2 is involved in the cross-talk between neoplastic cells 
and the TEMs surrounding their environment. Future research should be 
directed towards targeting these monocytes. Specifically Tie-2 could be a 
valid target to test, by performing intravital imaging of mice expressing Tie-
2-GFP under the control of a lentiviral vector. This way it might be possible 
to directly observe the effects of counteracting the recruitment of these 
bone marrow cells. More importantly a recent study showed that targeting 
tumor associated macrophages in a PDGF-β-driven glioma mouse model 
can be re-educated and used to oppose tumor growth [17]. Therefore by 
combining the inhibition of Tie-2 with the re-education of TAMs we could use 
the microenvironment to isolate the communication of tumor cells with their 
surrounding and neutralize them at the same time. Important readouts in 
this context would be the effects on vasculogenesis, on the balance of Ang1/2 
expression and tumor growth. Overall resetting the micro-environment and 
defeating the cross-talk between tumor cells and their surrounding might 
possibly counteract tumor evasion to therapy. 
Evaluating FPR1 as a drug target in GBM
FPR1 is highly upregulated in GBM and involved in many aspects of malignant 
cell activity in vitro and in vivo [12,18]. In Chapter 6 the observation that FPR1 
expression was absent in all primary GBM cell lines led to the conclusion that 
FPR1 expression might be dependent on microenvironmental factors. Such 
a factor could be interleukin-8 (IL-8), as several studies reported that IL-8 
might influence the expression of FPR1 by neutrophils [19,20]. In cancer, IL-8 
plays an important role as a regulatory factor in the microenvironment and 
is involved in resistance to chemotherapeutic drugs and angiogenesis [21]. 
IL-8 receptor and FPR1 activation induce the nuclear translocation of STAT3 
[12,21] while HIF1α is upregulated by FPR1 activation [12]. Furthermore 
both STAT3 and HIF1α are transcription factors of genes encoding for VEGF-A. 
Given that IL-8 has also been implicated in the upregulation of FPR1, the 
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possibility of an existing feedback loop arises. 
To date the only existing FPR1 studies with intracranial models are performed 
with U87 and compared to U87 containing siRNAs against FPR1. In none of 
the existing preclinical mouse models have intracranial tumors been treated 
with drugs targeting FPR1.  Therefore a next step would be the treatment 
of orthotopic U87 glioma mouse models with CHIPS. In addition to gain a 
larger repertoire of in vitro cell models expressing this receptor it will be 
necessary to investigate how the microenvironment affects the expression of 
FPR1. Overall more preclinical insights into the commitment and function of 
FPR1 in GBM are necessary in order to further define its role as a target for 
anti-cancer treatment.
The hurdles of AMD3100 and CHIPS 
An important hallmark of solid tumors resides in their heterogeneous 
nature characterized by the presence of various elements including tumor 
(stem) cells, endothelial cells, pericytes and tumor associated immune cells. 
Furthermore, multiple zones can be identified in GBM including a necrotic 
core, surrounded by a contrast enhancing bulk of tumor tissue, which in turn 
is surrounded by an infiltration area of individual tumor cells alternated by 
normal brain cells. Hypoxic as well as normoxic zones are present in the bulk 
of tumor. Although the blood brain barrier (BBB) is disrupted in the tumor 
bulk, the function of the BBB at the infiltration zone may vary. All these 
aspects will influence the microenvironment and the cellular make-up of the 
tumor at different zones. Targeting the microenvironment may thus affect 
the various regions of the tumor differently. 
CXCR4 is present on tumor cells and several types of tumor associated 
immune cells (Chapter 2)[22,23] including TEMs and TAMs [4], while FPR1 
is highly expressed by tumor cells and TAMs (Chapter 6) [24-26]. Therefore, 
targeting tumor cells and their microenvironment at both levels can be 
achieved by the CXCR4 inhibitor AMD3100 or the FPR1 inhibitor CHIPS.
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CXCR4 is highly present in various types of solid tumors and has been 
extensively described as a target for therapy. However in Chapter 4 by 
detecting increasing numbers of circulating tumor cells (CTCs) in a prostate 
cancer model after AMD3100 treatment we showed for the first time that 
CXCR4 inhibition in solid tumors causes unwanted effects. In addition previous 
findings showed that the administration of AMD3100 induces hematopoietic 
CXCR4-expressing stem cell mobilization and is useful for autologous 
transplantation in non-Hodgkin’s lymphoma and multiple myeloma patients 
[10,11]. Given that AMD3100 could cause the mobilization of tumor cells, 
potentially resulting in enhanced metastasis formation, the presence of CTCs 
should be closely monitored in future clinical studies with AMD3100. This 
was recently subject of investigation in a phase I clinical trial on a new CXCR4 
inhibitor (LY2510924). The authors reported an increase in CTCs in 6 out of 42 
treated patients with various types of solid tumors. Interestingly in two out 
of the three enrolled prostate cancer patients, the CTC count after treatment 
was increased [27]. In this clinical trial no GBM patients were enrolled and 
to date it remains unknown whether AMD3100 treatment could induce CTCs 
in GBM. 
FPR1 is another interesting target for therapy as its blockade can affect a 
great number of FPR1 downstream pathways related to the activation of this 
receptor [28]. FPR1 has a very potent and specific inhibitor called CHIPS, but 
interaction between FPR1 and CHIPS in the context of cancer has not yet 
been extensively investigated. In Chapter 5, our in vivo study showed slightly 
improved survival of animals with subcutaneously implanted human tumors 
following treatment with CHIPS. CHIPS’ serum half-life is short and therefore 
the use of osmotic pumps for drug administration instead of intraperitoneal 
administration might guarantee a more stable drug level for treatment 
of mice. However CHIPS has side effects as observed in a phase I study in 
human subjects. Therefore finding the proper window for treatment, in 
which CHIPS variants have sufficiently reduced immunogenicity, is essential 
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for future use of CHIPS in the context of cancer therapy. Specifically reduced 
immunogenicity would enable the use of higher concentrations of CHIPS in 
order to reach similar FPR1 activity as CHIPS wild type, but with less side 
effects. 
Generally a potential hurdle for GBM treatment is achieving the delivery of 
sufficient tumor drug levels across the BBB. Although the BBB is disrupted 
where the bulk of tumor cells reside, it is mostly intact at the site where 
infiltrated tumor cells are located   [29-31]. In Chapter 2 we discussed the 
possibility to combine bevacizumab with AMD3100 to obtain better treatment 
outcome in GBM patients. AMD3100 is a ~500Da bicyclam of which the 
ability to cross the BBB is not yet known. Currently in an ongoing phase I 
trial in recurrent-high grade glioma patients, the ability of AMD3100 to cross 
the BBB (NCT01339039, ClinicalTrials.gov) is addressed as a subquestion, 
although further specifications on the exact methods are not provided. 
In chapters 5, 6 and 7 we investigated the possibility to apply CHIPS as an 
anti-GBM drug. However the ability of CHIPS to freely cross the BBB has 
not yet been investigated but given the size of the protein (14.1 kDa) this 
may be a problem [32]. Various techniques exploiting delivery vehicles to 
carry therapeutic agents across biological barriers are emerging as a novel 
therapeutic strategy [33,34]. For instance one of these consists of attaching 
the treatment compound to other structures. This creates a pro-drug with 
improved lipophilic characteristics, which facilitates the diffusion through 
the BBB [35]. Also, microbubble focus ultrasound is an emerging technique 
currently under investigation and extensively described [36,37]. This system 
causes the temporary disruption of the BBB allowing the conveyance of 
large molecules across the barrier. Therefore it might be a suitable method 
for CHIPS and AMD3100 to achieve sufficient drug delivery at sites where 
the BBB could still be intact, thus changing the microenvironment at the 
infiltration zone of GBM.
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Conclusions
This thesis partly elucidates the role of FPR1 and CXCR4 in interacting with 
elements lodging in the tumor microenvironment. In resistance to cancer 
treatment, a bypass system originating from BMDC recruitment can play a 
role. To circumvent resistance this aspect could potentially be exploited in 
combination therapies in GBM. Specifically the upregulation of CXCR4 and its 
presence on Tie-2 expressing monocytes suggest an important role of these 
two receptors in tumor resistance to therapy. However targeting CXCR4 
as anticancer treatment with its inhibitor AMD3100 still requires careful 
investigation as it induced CTCs in the animal model.
FPR1 is highly expressed in GBM and directly interacts with mitochondrial 
peptides possibly originating from necrotic tumor microenvironment. 
Antagonizing FPR1 in a preclinical setting by using CHIPS, even suggested a 
survival benefit. However the use of CHIPS as a therapeutic drug necessitates 
the construction of a less immunogenic variant, which warrants further 
research. Overall understanding the regulatory mechanisms of FPR1 and 
CXCR4, operative within the tumor microenvironment might contribute to 
the development of better strategies for a more successful cancer treatment. 
Furthermore their inhibitors CHIPS and AMD3100 require additional insight 
into the proper application of these drugs as therapeutic agents. 
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